{'52WeekChange': 3.2903223,
 'SandP52WeekChange': None,
 'address1': 'Building D',
 'address2': '26 Harokmim Street Azrieli Center',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.99,
 'askSize': 800,
 'averageDailyVolume10Day': 1272975,
 'averageVolume': 1441215,
 'averageVolume10days': 1272975,
 'beta': 2.830812,
 'beta3Year': None,
 'bid': 14,
 'bidSize': 900,
 'bookValue': 1.624,
 'category': None,
 'circulatingSupply': None,
 'city': 'Holon',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.57,
 'dayLow': 13.85,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -32.628,
 'enterpriseToRevenue': None,
 'enterpriseValue': 876877184,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 3 765 8555',
 'fiftyDayAverage': 15.019428,
 'fiftyTwoWeekHigh': 17.85,
 'fiftyTwoWeekLow': 2.96,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 70152132,
 'forwardEps': -0.51,
 'forwardPE': -27.754902,
 'fromCurrency': None,
 'fullTimeEmployees': 61,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00183,
 'heldPercentInstitutions': 0.31243,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cgen.com',
 'longBusinessSummary': 'Compugen Ltd., a clinical-stage therapeutic discovery '
                        'and development company, engages in the research, '
                        'development, and commercialization of therapeutic and '
                        'product candidates in Israel, the United States, and '
                        "Europe. The company's immuno-oncology pipeline "
                        'consists of COM701, an anti-PVRIG antibody that is in '
                        'Phase I clinical study used for the treatment of '
                        'solid tumors; BAY 1905254, a therapeutic antibody '
                        'targeting ILDR2, which is in Phase I clinical study '
                        'in patients with solid tumors; and COM902, a '
                        'therapeutic antibody targeting TIGIT. Its therapeutic '
                        'pipeline also includes early-stage immuno-oncology '
                        'programs focused primarily on myeloid targets. The '
                        'company has collaboration agreement with Bayer Pharma '
                        'AG for the research, development, and '
                        'commercialization of antibody-based therapeutics for '
                        "antibody-based therapeutics against the company's "
                        'immune checkpoint regulators; Bristol-Myers Squibb to '
                        'evaluate the safety and tolerability of COM701 in '
                        "combination with Bristol-Myers Squibb's PD-1 immune "
                        'checkpoint inhibitor Opdivo in patients with advanced '
                        'solid tumors; and Johns Hopkins School of Medicine to '
                        'evaluate novel T cell and myeloid checkpoint targets. '
                        'It has license agreement with AstraZeneca for the '
                        'development of bi-specific and multi-specific '
                        'immuno-oncology antibody products. Compugen Ltd. was '
                        'incorporated in 1993 and is headquartered in Holon, '
                        'Israel.',
 'longName': 'Compugen Ltd.',
 'market': 'us_market',
 'marketCap': 1175223040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_166115',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -26057000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.5,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 3 765 8585',
 'previousClose': 14.63,
 'priceHint': 2,
 'priceToBook': 8.716133,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.57,
 'regularMarketDayLow': 13.85,
 'regularMarketOpen': 14.5,
 'regularMarketPreviousClose': 14.63,
 'regularMarketPrice': 14.5,
 'regularMarketVolume': 1844659,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 79275104,
 'sharesPercentSharesOut': 0.081,
 'sharesShort': 6418532,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4415980,
 'shortName': 'Compugen Ltd.',
 'shortPercentOfFloat': 0.1192,
 'shortRatio': 4.53,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'CGEN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.394,
 'twoHundredDayAverage': 11.378777,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '1985262d-ab80-3c43-a2e1-6782924ab738',
 'volume': 1844659,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cgen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '5885849'}